Texas Capital Bancshares Inc/Tx (TCBIO) Research & Development (2011 - 2026)

Texas Capital Bancshares (TCBIO) has reported Research & Development for 16 consecutive years, with $28.5 million the latest figure, recorded in Q2 2026.

• Quarterly Research & Development rose 17.19% year-over-year to $28.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $106.6 million (up 8.83% YoY) and the FY2025 annual result came in at $98.9 million, up 6.2% from the prior year.
• Research & Development grew to $28.5 million in Q2 2026 per TCBIO's latest filing, from $27.2 million in the prior quarter.
• Over the last five years, Research & Development for TCBIO reached as high as $28.5 million in Q2 2026 and fell as low as $14.7 million in Q1 2022.
• A 5-year average of $22.1 million and a median of $22.8 million in 2023 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2022 — Research & Development sank 34.91% — and 2024, when it jumped 32.36%.
• Year by year, Research & Development stood at $20.4 million in 2022, then rose by 15.53% to $23.6 million in 2023, then gained by 1.69% to $24.0 million in 2024, then climbed by 9.56% to $26.3 million in 2025, then increased by 8.33% to $28.5 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $28.5 million, $27.2 million, and $26.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.